Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01.

ABSTRACT:

Background

VRC01 is a human IgG1 broadly neutralizing antibody (bnAb) that binds to the HIV-1 envelope glycoprotein. It is being evaluated in two ongoing Phase 2b trials, the first efficacy assessment of a passively-administered bnAb for HIV-1 prevention. HVTN 104 was a phase 1 trial of VRC01.

Setting

We measured serum concentrations and serum neutralization of VRC01 in 1079 longitudinal samples collected after passive administration of VRC01 in 84 HVTN 104 participants. As assays for measuring VRC01 serum neutralization titers are resource-intensive, we investigated approaches to predicting such titers.

Methods

Serum concentration was measured using an anti-idiotypic ELISA assay. Serum neutralization ID50 titers and in vitro neutralization potency IC50 of the VRC01 c

SUBMITTER: Huang Y 

PROVIDER: S-EPMC7594341 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature